Table 2_A prediction model and risk stratification tool for survival by chemotherapy in in

Fang Yang published a dataset on 2026-06-04 containing clinical records for 1,349 patients with invasive micropapillary carcinoma of the breast. The data includes 1,150 patients from the SEER database (2010–2018) and an external validation cohort of 199 patients from Nanjing Drum Tower Hospital. It was used to develop and validate a risk stratification model for survival outcomes based on chemotherapy treatment.

Use Cases

• Developing survival prediction models based on clinical variables like marital status, tumor size, subtype, and radiotherapy history.
• Validating risk stratification tools for identifying high-risk patients who may benefit from chemotherapy.
• Comparing overall survival and breast cancer-specific survival outcomes between patient cohorts.
• Conducting propensity score matching analyses to assess treatment impacts using real-world clinical data.

Strengths

• Includes data from two distinct cohorts totaling 1,349 patient records.
• Model was externally validated, confirming its ability to identify differential survival associations with chemotherapy.
• Data covers a specific cancer subtype (invasive micropapillary carcinoma) over an 8-year period (2010–2018).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for individual tables is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the SEER database and a single Chinese hospital.

Provenance

Source

SEER database and Nanjing Drum Tower Hospital.

Collection Method

Retrospective study analyzing patient records.

Time Range

2010–2018 for the SEER cohort.

Freshness

Last updated 2026-06-04 04:30:30; freshness should be verified.

Geography

United States (SEER) and China (Nanjing).